Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases
| Autor: | Vaclav Liska, Skalicky T, Radek Kucera, Jiri Ferda, Daniel Lysák, Jakub Fichtl, Inka Treskova, Jan Bruha, Vladislav Treska, Jaroslav Ludvik, Ondrej Topolcan |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.diagnostic_test business.industry Liver volume Computed tomography General Medicine Gastroenterology 030218 nuclear medicine & medical imaging Resection 03 medical and health sciences Haematopoiesis 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Internal medicine Portal vein embolization Medicine In patient Stem cell business R0 resection |
| Zdroj: | Anticancer Research. 38:5531-5537 |
| ISSN: | 1791-7530 0250-7005 |
| Popis: | BACKGROUND Portal vein embolization (PVE) and PVE with autologous mesenchymal stem cell application (PVE-MSC) increases future liver remnant volume (FLRV). The aim of this study was to compare both methods from the aspect of FLRV growth, progression of colorectal liver metastases (CLM), CLM resectability and long-term results. PATIENTS AND METHODS Fifty-five patients with CLM and insufficient FLRV were included in the study. FLVR growth and CLM volume were evaluated using computed tomography. Liver resection was performed in patients with FLVR >30% of total liver volume. RESULTS In the PVE (N=27) group, FLRV growth was observed in 23 patients (85.2%) and in 100% of patients in the PVE-MSC (N=28) group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|